A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
- Conditions
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 650
- Registration Number
- NCT05197192
- Locations
- 🇩🇪
Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany
🇩🇪DRK Kliniken Berlin Köpenick, Berlin, Germany
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 53
- Registration Number
- NCT04883749
- Locations
- 🇩🇪
Universitaetsklinikum Essen, Essen, Germany
🇩🇪Onkologische Kooperation Harz, Goslar, Germany
🇩🇪OncoResearch Lerchenfeld, Hamburg, Germany
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 897
- Registration Number
- NCT04608318
- Locations
- 🇩🇪
Klinikum rechts der Isar - Technische Universitaet Muenchen, München, Germany
🇳🇱Franciscus Vlietland, Schiedam, Netherlands
🇸🇪Hallands Sjukhus, Varberg, Sweden
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
- Conditions
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 42
- Registration Number
- NCT04515238
- Locations
- 🇩🇪
Onkologische Schwerpunktpraxis, Esslingen, Germany
🇩🇪Hamatologische/Onkologische Gemeinschaftspraxis, Augsburg, Germany
🇩🇪Universitätsklinik Köln, Köln, Germany
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 83
- Registration Number
- NCT04271956
- Locations
- 🇦🇹
Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria
🇩🇪Brüderkrankenhaus St. Josef Paderborn, Paderborn, Germany
🇩🇪Uniklinik Köln, Cologne, Germany
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL
- Conditions
- Interventions
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 46
- Registration Number
- NCT03787264
- Locations
- 🇩🇪
Gemeinschaftspraxis Hämatologie Onkologie, Dresden, Germany
🇩🇪Universitatsklinik Carl Gustav Carus, Dresden, Germany
🇩🇪Praxis fuer Haematologie und Onkologie, Koblenz, Germany
Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 3
- Registration Number
- NCT03153514
- Locations
- 🇩🇪
Universitätsklinikum Leipzig, Leipzig, Germany
🇩🇪Universitätsklinikum Magdeburg, Magdeburg, Germany
🇩🇪Universitätsklinikum Essen, Essen, Germany
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 926
- Registration Number
- NCT02950051
- Locations
- 🇮🇱
Kaplan Medical Center, Rechovot, Israel
🇳🇱Canisius-Wilhelmina ZH, Nijmegen, Netherlands
🇳🇱Antonius Ziekenhuis Sneek, Sneek, Netherlands
Registry of the German CLL Study Group
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 8000
- Registration Number
- NCT02863692
- Locations
- 🇩🇪
BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Sachsen, Germany
Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 515
- Registration Number
- NCT02863718
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany